Pragmatic trial design elements showed a different impact on trial interpretation and feasibility than explanatory elements

Journal of Clinical Epidemiology

Volumn 77, Issue , 2016, Pages 95-100

  Nieuwenhuis, Joost B ^a   Irving, Elaine ^b   Oude Rengerink, Katrien ^a   Lloyd, Emily ^b   Goetz, Iris ^c   Grobbee, Diederick E ^a   Stolk, Pieter ^a   Groenwold, Rolf H H ^a   Zuidgeest, Mira G P ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b GLAXOSMITHKLINE   (United Kingdom)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

Explanatory trial; Generalizability; Operational feasibility; Pragmatic clinical trials; Precision; Real world evidence; Trial design; Validity

Indexed keywords

DRUG;

ACCURACY; ARTICLE; CLINICAL RESEARCH; FEASIBILITY STUDY; FOLLOW UP; HUMAN; MEDICATION COMPLIANCE; MEDLINE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); STANDARDIZATION; STUDY DESIGN; VALIDITY; EPIDEMIOLOGY; METHODOLOGY;

EPIDEMIOLOGIC STUDIES; FEASIBILITY STUDIES; HUMANS; RESEARCH DESIGN;

EID: 84994460693     PISSN: 08954356     EISSN: 18785921     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2016.04.010     Document Type: Article

References (29)

1. [1] Helms, P.J., “Real World” pragmatic clinical trials: what are they and what do they tell us?. Pediatr Allergy Immunol 13 (2002), 4–9.
2. [2] Hoffman, A., Montgomery, R., Aubry, W., Tunis, S.R., How best to engage patients, doctors, and other stakeholders in designing comparative effectiveness studies. Health Aff (Millwood) 29 (2010), 1834–1841.
3. [3] Eichler, H.G., Bloechl-Daum, B., Abadie, E., Barnett, D., König, F., Pearson, S., Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers. Nat Rev Drug Discov 9 (2010), 277–291.
4. [4] Choudhry, N.K., Shrank, W.H., Implementing randomized effectiveness trials in large insurance systems. J Clin Epidemiol 66 (2013), S5–S11.
5. [5] Buesching, D.P., Luce, B.R., Berger, M.L., The role of private industry in pragmatic comparative effectiveness trials. J Comp Eff Res 1 (2012), 147–156.
6. [6] Schwartz, D., Lellouch, J., Explanatory and pragmatic attitudes in therapeutical trials. J Chronic Dis 20 (1967), 637–648.
7. [7] McCambridge, J., Witton, J., Elbourne, D.R., Systematic review of the Hawthorne effect: new concepts are needed to study research participation effects. J Clin Epidemiol 67 (2014), 267–277.
8. [8] Thorpe, K.E., Zwarenstein, M., Oxman, A.D., Treweek, S., Furberg, C.D., Altman, D.G., et al. A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. J Clin Epidemiol 62 (2009), 464–475.
9. [9] Loudon, K., Treweek, S., Sullivan, F., Donnan, P., Thorpe, K.E., Zwarenstein, M., The PRECIS-2 tool: designing trials that are fit for purpose. BMJ, 350, 2015, h2147.
10. [10] IMI Get Real consortium: www.imi-getreal.eu Accessed May 24, 2016.
11. [11] Grobbee, D., Hoes, A., Clinical epidemiology: principles, methods, and applications for clinical research. 2nd ed., 2014, Jones & Bartlett Learning, Burlington, USA.
12. [12] Rothman, K.J., Greenland, S., Lash, T.L., Modern epidemiology. 2008, Lippincott Williams & Wilkins, Philadelphia, USA.
13. [13] Geddes, J., Goodwin, G., Rendell, J., Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet 375 (2010), 385–395.
14. [14] Manschreck, T.C., The CATIE schizophrenia trial: results, impact, controversy. Harv Rev Psychiatry 15 (2007), 245–258.
15. [15] Zamorano, J., Erdine, S., Pavia, A., Kim, J.H., Al-Khadra, A., Westergaard, M., et al. Proactive multiple cardiovascular risk factor management compared with usual care in patients with hypertension and additional risk factors: the CRUCIAL trial. Curr Med Res Opin 27 (2011), 821–833.
16. [16] Alphs, L., Anand, R., Islam, A., The international suicide prevention trial (interSePT): rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patients. Schizophr Bull 30 (2004), 577–586.
17. [17] Bakerly, N.D., The Salford lung study protocol: a prospective, randomized real-world effectiveness trial in Chronic Obstructive Pulmonary Disease (COPD). Am J Respir Crit Care Med, 187, 2013, A2159 [Abstract].
18. [18] Rush, A.J., Fava, M., Wisniewski, S.R., Lavori, P.W., Trivedi, M.H., Sackeim, H.A., et al., STAR*D Investigators Group. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials 25 (2004), 119–142.
19. [19] Strom, B.L., Eng, S.M., Fiach, G., Reynolds, R.F., D'Agostino, R.B., Ruskin, J., et al. Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: the Ziprasidone observational study of cardiac outcomes (ZODIAC). Am J Psychiatry 168 (2011), 193–201.
20. [20] New, J.P., Bakerly, N.D., Leather, D., Woodcock, A., Obtaining real-world evidence: the Salford lung study. Thorax 69 (2014), 1152–1154.
21. [21] Friedman, E.S., Thase, M.E., Kornblith, S.J., Wisniewski, S.R., Briggs, M.M., Rush, A.J., et al. The implementation of cognitive therapy in STAR*D. Cognit Ther Res 28 (2004), 819–833.
22. [22] Alpert, J.E., Biggs, M.M., Davis, L., Shores-Wilson, K., Harlan, W.R., Schneider, G.W., et al. Enrolling research subjects from clinical practice: ethical and procedural issues in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial. Psychiatry Res 141 (2006), 193–200.
23. [23] Warden, D., Rush, A.J., Trivedi, M., Ritz, L., Stegman, D., Wisniewski, S.R., Quality improvement methods as applied to a multicenter effectiveness trial—STAR*D. Contemp Clin Trials 26 (2005), 95–112.
24. [24] Zamorano, J., Erdine, S., Lopz, A., Kim, J.H., Khadra, A., Westergaard, M., et al. Design and rationale of real-life study to compare treatment strategies for cardiovascular risk factors: the CRUCIAL study. Postgrad Med 122 (2010), 7–15.
25. [25] Meltzer, H.Y., Alphs, L., Green, A.I., Clozapine treatment for suicidality in schizophrenia: international suicide prevention trial (intersept). Arch Gen Psychiatry 60 (2003), 82–91.
26. [26] Potkin, S.G., Alphs, L., Hsu, C., Ranga Rama Krishnan, K., Anand, R., Young, F.K., et al. Predicting suicidal risk in schizophrenic and schizoaffective patients in a prospective two-year trial. Biol Psychiatry 54 (2003), 444–452.
27. [27] Sakinofsky, I., Heila, H., Krishnan, R., Estimating suicidality as an outcome measure in clinical trials of suicide in schizophrenia. Schizophr Bull 30 (2004), 587–598.
28. [28] Dransfield, M.T., Bourbeau, J., Jones, P.W., Hanania, N.A., Mahler, D.A., Vestbo, J., et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med 1:3 (2013), 210–223.
29. [29] Blaschke, T.F., Osterberg, L., Vrijens, B., Urquhart, J., Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories. Annu Rev Pharmacol Toxicol 52 (2012), 275–301.